A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis
This study is for adults with non-infectious uveitis, which is a condition causing inflammation inside the eye, affecting the middle, back, or all parts of the eye. Researchers are testing a new medicine called Izokibep to see how well it works to prevent the condition from getting worse compared to a 'dummy' treatment (placebo). They will also be carefully checking for any side effects. The main goal is to find out if Izokibep can help keep the eye condition stable for longer. They'll also look at things like vision, eye pain, and the thickness of parts of the eye.
At a glance
What is this study about?
This clinical trial is designed to investigate a new treatment, Izokibep, for people who have a condition called uveitis. Uveitis is when the inside of your eye becomes inflamed, which can cause pain, redness, blurry vision, and can sometimes lead to serious vision problems if not treated. This particular study focuses on uveitis that isn't caused by an infection, and it specifically looks at inflammation affecting the middle, back, or all parts of the eye.
The main purpose of this study is to see if Izokibep can effectively stop the uveitis from flaring up or getting worse, compared to a placebo (a treatment that looks like the real medicine but contains no active drug). Researchers will also be keeping a very close eye on any side effects to make sure the treatment is safe. Understanding how well the medicine works and if it has any unwanted effects is crucial before it can be considered for wider use.
By comparing Izokibep to a placebo, the researchers can clearly understand its benefits. They’ll be measuring a range of things, including how long it takes for someone's condition to get worse, whether the inflammation settles down, how well people can see, and even how daily activities are affected. This detailed approach helps them build a complete picture of Izokibep's potential as a new treatment option for uveitis.
Key takeaways
- New medicine (Izokibep) being tested for eye inflammation (uveitis).
- Compares Izokibep to a dummy treatment (placebo).
- Focuses on non-infectious uveitis in adults.
- Aims to see if the medicine stops uveitis from worsening.
- Safety and side effects will be carefully monitored.
- Involves regular clinic visits and eye tests.
Who may be eligible?
To be considered for this study, you need to be an adult, 18 years old or older. The study is open to both men and women.
You would specifically need to have been diagnosed with a type of eye inflammation called non-infectious uveitis. This means your eye inflammation isn't caused by germs like bacteria or viruses, and it affects the middle, back, or all parts of your eye. The research team will have other specific health requirements to make sure the study medication is suitable and safe for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have non-infectious uveitis?
- Does your uveitis affect the middle, back, or all parts of your eye?
- Are you comfortable with regular clinic visits for eye checks and blood tests?
- Are you able to receive medication by injection?
What does participation involve?
If you decide to take part in this study, you would receive either the new medicine, Izokibep, or a placebo (a 'dummy' treatment with no active drug). You wouldn't know which one you are receiving, nor would your doctors in the study, which helps ensure the results are fair. Both are given by injection. You would have regular visits to the clinic for various check-ups and tests. These will include eye exams, vision tests, blood tests, and possibly scans of your eye to see how the inflammation is progressing.
The research team will closely monitor your general health, vital signs (like blood pressure), and any side effects you might experience. They will also ask you to fill out questionnaires about your vision and how you're feeling. The total duration of your participation in the study, including the treatment period and any follow-up visits, would be explained in detail by the study team.
Potential risks and benefits
Locations (6)
- —UnverifiedFrance
- —UnverifiedCzechia
- —UnverifiedAustria
- —UnverifiedSpain
- —UnverifiedGermany
- —UnverifiedItaly
Common questions
What is uveitis?
Uveitis is inflammation inside your eye, which can cause redness, pain, and blurry vision. This study focuses on a type not caused by infection.
What is Izokibep?
Izokibep is a new medicine being tested in this study to see if it can reduce eye inflammation and prevent uveitis from getting worse.
What is a 'placebo'?
A placebo is a 'dummy' treatment that looks like the real medicine but contains no active drug. It's used to fairly compare the new medicine's effects.
How will my vision be checked?
Your vision will be checked using standard eye charts, and there might be specific questionnaires to understand how your vision affects your daily life.
Will I have to have injections?
Yes, both the investigational medicine and the placebo are given by injection in this study.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.